Physician profile
Donald E Saunders
NPI 1861485088
$5,790.84
in general payments reported to CMS, 2019-2025
33 companies · $884 in 2025
The $884 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $730 · 2021: $336 · 2022: $214 · 2023: $1,142 · 2024: $970 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $832.95 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $638.64 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $533.56 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $491.80 | 2019-2024 | Lifevest |
| Pfizer INC. | $434.37 | 2019-2025 | |
| Abbott Laboratories | $379.99 | 2019-2023 | Amplatzer Amulet |
| Philips North America LLC | $307.99 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions, (5091) Amb Mon & Diag Und |
| Janssen Pharmaceuticals, INC | $238.63 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.70 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $200.61 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $161.19 | 2022-2025 | Onpattro, Amvuttra |
| Sanofi-Aventis U.S. LLC | $156.40 | 2019 | |
| Novo Nordisk INC | $143.46 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $138.22 | 2023-2025 | |
| Boston Scientific Corporation | $129.96 | 2019-2023 | Watchman Access System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $95.72 | 2023-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Kiniksa Pharmaceuticals International, Plc | $88.19 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $74.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $61.35 | 2021-2023 | Verquvo |
| Cvrx, INC. | $60.69 | 2023-2024 | Barostim Neo System |
| Penumbra, INC. | $57.42 | 2019 | |
| Esperion Therapeutics, INC. | $45.91 | 2023-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $45.58 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, Ltd. | $40.28 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $37.04 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $36.06 | 2023 | Inpefa |
| Vital Connect, INC | $31.98 | 2024 | Vitalpatch Rtm |
| Heartflow, INC. | $31.45 | 2019 | |
| Bardy Diagnostics, INC. | $26.00 | 2019 | |
| Biotronik INC. | $20.93 | 2024 | |
| Medtronic, INC. | $18.36 | 2021 | |
| Cranial Technologies, INC | $14.14 | 2020 | |
| Atricure, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.